Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05758896 · ClinicalTrials.gov registry record · Phase 2
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
A Phase 2 study of Contrast Induced Acute Kidney Injury, sponsored by Aptabio Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 14
- Study locations
NCT05758896: Recruiting Phase 2 study of Contrast Induced Acute Kidney Injury, sponsored by Aptabio Therapeutics.
NCT05758896 is a Phase 2 study of Contrast Induced Acute Kidney Injury that is actively recruiting participants, run by Aptabio Therapeutics. The registered enrollment target is 280 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher). The trial reports 14 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05758896, a Phase 2 study of Contrast Induced Acute Kidney Injury, is actively recruiting participants, sponsored by Aptabio Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 280 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.
Primary Outcome
Number of adverse events
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Isuzinaxib (APX-115)
Study Locations (14)
Other
- Kangwon National University Hospital - Chuncheon
- Keimyung University Dongsan Hospital - Daegu
- Chungnam National University Hospital - Daejeon
- Inje University Ilsan Paik Hospital - Goyang
- Chonnam National University Hospital - Gwangju
- Seoul National University Bundang Hospital - Seongnam-si
- Kangbuk Samsung Hospital - Seoul
- Korea University Anam Hospital - Seoul
- Samsung Medical Center - Seoul
- Seoul National University Hospital - Seoul
- The Catholic University of Korea Seoul St. Mary's Hospital - Seoul
- The Catholic University of Korea St. Vincent's Hospital - Suwon
- Ulsan University Hospital - Ulsan
Texas
- Baylor Scott & White Research Institute - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT05758896 shows while recruiting
NCT05758896 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher).
The record links to 1 condition, with Contrast Induced Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05758896 lists 14 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT05758896 about?
NCT05758896 is a clinical study titled "Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI". This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 280 patients will be random...
What is the current status of trial NCT05758896?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2023-12-27. Estimated completion is 2026-12-31.
What conditions does trial NCT05758896 study?
This clinical trial studies the following conditions: Contrast Induced Acute Kidney Injury.
What interventions are being tested in trial NCT05758896?
The interventions under investigation include: Placebo (DRUG), Isuzinaxib (APX-115) (DRUG).
Who is sponsoring clinical trial NCT05758896?
This trial is sponsored by Aptabio Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05758896 being conducted?
This trial has 14 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contrast Induced Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05758896's enrollment target sits among peer trials
280 196th of 2000 higher than 1,801 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI